

**REMARKS**

**Status**

Claims 1-21 are pending in this application.

**Discussion**

**RESTRICTION RESPONSE**

The Examiner has required restriction in the above-identified application and has divided the claims as follows:

Group I--Claims 1-17, drawn to compounds and pharmaceutical compositions of formula I.

Group II—Claims 18-21, drawn to methods of treating.

Applicants have elected Group I, Claims 1-17.

Applicants respectfully request Rejoinder of Group II, Claims 18-21, once allowable subject matter has been found in Group I. Claims 18-21 depend from the product claims.

**ELECTION RESPONSE**

Applicants have elected the species of Example 3 for examination purposes. Applicants respectfully request that, should the Examiner find the elected species allowable, the search be extended, since Applicants are entitled to consideration of claims to a reasonable number of disclosed species in addition to the elected species as provided for under 37 CFR 1.146.

In view of the foregoing, Applicants submit that the application is now in condition for examination on the merits. Early notification of such action is earnestly solicited. If the Examiner has any questions or believes further discussion will aid examination and advance prosecution of the application, a telephone call to the undersigned is invited.

**DOCKET NO.: PH-7466**  
**USSN: 10/801,518**

**Restriction/Election**

Respectfully submitted,

Date: December 8 , 2005



Jing G. Sun, Ph.D.  
Registration No. 45,914  
Telephone No. (609) 252-3791  
Facsimile No. (609) 252-4526

**Please forward all future written correspondence relating to this application to:**

Louis J. Wille  
Patent Department  
Bristol-Myers Squibb Company  
P.O. Box 4000  
Princeton, NJ 08543-4000